Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies
| Autor: | Limentani Sa |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
medicine.medical_specialty
Genetic enhancement Hemophilia A Haemophilia Recombinant factor viii Factor IX Cost Savings hemic and lymphatic diseases medicine Humans Effective treatment Haemophilia B Intensive care medicine Factor X Deficiency Clinical Trials as Topic Factor VIII business.industry Environmental resource management Genetic Therapy Hematology General Medicine medicine.disease Recombinant Proteins Clinical trial Safety business Forecasting Recombinant factor IX medicine.drug |
| Zdroj: | Blood Coagulation & Fibrinolysis. 5:S81-S84 |
| ISSN: | 0957-5235 |
| DOI: | 10.1097/00001721-199412004-00021 |
| Popis: | Future treatment for patients with haemophilia may include the use of either gene therapy, recombinant factor VIII, recombinant factor IX, or high-purity factor IX. Studies on gene therapy are still at the pre-clinical stage, while clinical trials of recombinant factor IX are expected to start by mid-1995. High-purity factor IX concentrates are available and are the treatment of choice for patients with haemophilia B in the absence of a source of recombinant factor IX. Recombinant factor VIII provides a renewable and unlimited source of factor VIII, and is a safe and effective treatment for haemophilia A. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|